Filing Analysis
Kalaris Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- The report covers financial results for the quarter ended June 30, 2026.
- Results were announced via press release on August 11, 2026.
- The filing is made pursuant to Item 2.02 of Form 8-K.
Kalaris Therapeutics announced the appointment of Liisa Bayko as new CFO and Treasurer, effective July 20, 2026. Simultaneously, the company reported the resignation of Chief Accounting Officer Brett Hagen and the appointment of Amy Vandekop as interim principal accounting officer.
🚩 Red Flags
- Simultaneous departure of the Chief Accounting Officer and appointment of a new CFO suggests potential turnover in the finance department.
- The transition to an 'interim' principal accounting officer can sometimes indicate internal instability or rapid shifts in financial leadership.
📋 Key Facts
- Liisa Bayko appointed CFO/Treasurer and Principal Financial Officer, effective July 20, 2026.
- Ms. Bayko's compensation includes a $475,000 base salary and a target annual bonus of up to 40%.
- Ms. Bayko was granted an option to purchase up to 220,000 shares of common stock with a 4-year vesting schedule.
- Chief Accounting Officer Brett Hagen resigned effective July 27, 2026.
- Amy Vandekop (Corporate Controller) appointed as interim principal accounting officer effective July 27, 2026.
Kalaris Therapeutics announced positive expanded Phase 1a single ascending dose (SAD) clinical trial data for its TH103 candidate in treating neovascular age-related macular degeneration (nAMD). The data suggests improved visual acuity and retinal anatomy, alongside extended time to retreatment compared to existing VEGF agents.
🚩 Red Flags
- One patient previously experienced transient intraocular inflammation (IOI) at the 5 mg dose.
- Forward-looking statements include risks regarding the ability to obtain sufficient additional capital to continue development.
📋 Key Facts
- Expanded Phase 1a SAD dataset includes 17 treatment-naïve patients and 3 treatment-experienced patients.
- All 20 patients completed six months of follow-up.
- 41% of treatment-naïve patients required first retreatment at four months or later; 29% required no additional anti-VEGF treatment during the six-month period.
- Mean BCVA improvement of 9.2 letters and a 93% reduction in central subfield intraretinal fluid were observed after one injection.
- TH103 showed 27-to-53-fold lower Cmax compared to current leading anti-VEGF agents on a molar equivalence basis, suggesting higher intraocular retention.
- No cases of intraocular inflammation (IOI) in the 6 patients treated at the 2.5 mg dose using adjusted manufacturing processes.
Kalaris Therapeutics announced the immediate resignation of Dr. Morana Jovan-Embiricos from the Board and Audit Committee, effective July 3, 2026. The company simultaneously appointed Laurie Keating to the Board and Audit Committee, effective August 1, 2026.
🚩 Red Flags
- Immediate resignation of a Board/Audit Committee member (though stated as non-disagreement).
📋 Key Facts
- Dr. Morana Jovan-Embiricos resigned as a Director and Audit Committee member on July 3, 2026.
- The resignation was not due to any disagreement regarding company operations, policies, or practices.
- Laurie Keating elected to the Board and Audit Committee effective August 1, 2026.
- Ms. Keating will receive $40,000 annual cash compensation for Board service and $7,500 for Audit Committee service.
- Ms. Keating granted an option to purchase 18,000 shares of common stock vesting over three years starting August 1, 2026.
Kalaris Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. The meeting resulted in the election of three Class III directors, approval of executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Election of Napoleone Ferrara, M.D., David Hallal, and Leone Patterson as Class III directors for three-year terms expiring in 2029.
- Approval of named executive officer compensation on a non-binding advisory basis (15,852,844 votes For vs 495,763 Against).
- Stockholders recommended that future advisory votes on executive compensation be held every year (16,336,117 votes for 'One Year').
- Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Kalaris Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a routine update on the company's operations and financial condition.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026
- Press release issued on May 12, 2026
- Filing submitted under Item 2.02 (Results of Operations and Financial Condition)
- Information is furnished and not deemed filed for Section 18 purposes
Kalaris Therapeutics announced the resignation of CFO Matthew Gall, effective April 14, 2026. Brett Hagen, the company's current Chief Accounting Officer, will assume the role of Principal Financial Officer.
🚩 Red Flags
- Short notice period (6 days) between the resignation notification and the effective separation date.
- The company is a micro-cap biotech where CFO turnover can often precede capital raises or strategic shifts.
📋 Key Facts
- Matthew Gall notified the company of his resignation as CFO on April 8, 2026.
- The resignation is effective April 14, 2026, representing a short notice period of six days.
- Brett Hagen, 53, has been appointed as the Principal Financial Officer effective April 14, 2026.
- Hagen has served as the company's Chief Accounting Officer since January 2019.
- No changes were made to Hagen's compensatory plans in connection with the appointment.
Kalaris Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025. The results were released via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing was made on March 17, 2026, reporting on the fiscal year ended December 31, 2025.
- The report is filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results is included as Exhibit 99.1.
- The company is listed on The Nasdaq Global Market under the symbol KLRS.
Kalaris Therapeutics furnished an updated corporate presentation for the Leerink Partners Global Healthcare Conference on March 9, 2026. The presentation provides updated clinical timelines for its lead candidate TH103 and revised cash runway guidance.
🚩 Red Flags
- Forward-looking statements highlight risks related to the inability to obtain sufficient additional capital to advance product candidates
📋 Key Facts
- Updated timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103
- Updated timelines for initiating Phase 3 clinical development of TH103
- Provision of updated cash runway guidance
- Presentation scheduled for use at the Leerink Partners Global Healthcare Conference
Kalaris Therapeutics entered into a securities purchase agreement to conduct a private placement of 4.2 million shares and 800,000 pre-funded warrants at $10.00 per share, aiming to raise approximately $50 million in gross proceeds.
🚩 Red Flags
- Issuance of pre-funded warrants with extremely low exercise prices ($0.0001) can lead to significant future dilution.
- Registration Rights Agreement requires the company to file a registration statement by April 1, 2026, and includes potential liquidated damages if deadlines are missed.
📋 Key Facts
- Private placement of 4,200,000 common shares at $10.00 per share.
- Issuance of 800,000 pre-funded warrants at $9.9999 per warrant (exercise price $0.0001).
- Expected gross proceeds: approximately $50.0 million.
- Closing expected on or about December 19, 2025.
- Lead placement agents include Morgan Stanley & Co. LLC and Leerink Partners LLC; William Blair & Company, L.L.C. is also acting as an agent.
- The company expects the proceeds to extend cash runway into Q3 2027.
Kalaris Therapeutics announced positive initial Phase 1a single ascending dose (SAD) clinical trial data for its lead candidate, TH103, in treating neovascular age-related macular degeneration (nAMD). The data showed clinically meaningful improvements in vision and retinal anatomy with a favorable safety profile.
🚩 Red Flags
- Early clinical trials carry high inherent risk of failure in later stages.
- Initial occurrence of transient intraocular inflammation (IOI) due to manufacturing impurities (though addressed).
📋 Key Facts
- Phase 1a SAD trial evaluated three dose levels (0.5 mg, 1.5 mg, 2.5 mg) in 13 treatment-naïve nAMD patients.
- Clinical results showed mean improvement in Best Corrected Visual Acuity (BCVA) and significant reduction in central subfield intraretinal fluid (~95% reduction).
- Pharmacokinetic profile showed plasma levels of TH103 were 27 to 51-fold lower than current leading anti-VEGF agents, suggesting enhanced intraocular retention.
- 31% of patients required no additional anti-VEGF treatment during the six-month follow-up after a single injection.
- Two cases of transient, mild-moderate intraocular inflammation (IOI) were observed at Day 4 in the 2.5 mg dose group, attributed to host cell protein; subsequent manufacturing improvements eliminated new instances.
Kalaris Therapeutics, Inc. filed an 8-K to furnish its quarterly earnings press release for the period ended September 30, 2025.
📋 Key Facts
- The filing was made on November 12, 2025.
- The report pertains to financial results for the quarter ended September 30, 2025.
- The company is an emerging growth company.
- Exhibit 99.1 contains the actual press release detailing the financial performance.
Kalaris Therapeutics, Inc. announced the appointment of Matthew Gall as Chief Financial Officer and Treasurer, effective November 3, 2025. This transition results in Brett Hagan stepping down from his role as principal financial officer, though he will remain as principal accounting officer.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Matthew Gall appointed CFO, Treasurer, and Principal Financial Officer effective Nov 3, 2025.
- Gall's previous experience includes roles at iTeos Therapeutics and Sarepta Therapeutics.
- Annualized base salary for Gall is $485,000 with a target annual bonus of up to 40%.
- Grant of 235,000 stock options to Gall, vesting over approximately four years (25% on first anniversary).
- Brett Hagan will cease serving as principal financial officer but remains Chief Accounting Officer.
- Employment agreement includes standard non-compete and severance provisions in the event of a change in control.
Kalaris Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on August 12, 2025. The meeting resulted in the election of two Class II directors and the ratification of Deloitte & Touche LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on August 12, 2025.
- Srinivas Akkaraju, M.D., Ph.D. elected to Class II director (term expiring 2028).
- Andrew Oxtoby elected to Class II director (term expiring 2028).
- Deloitte & Touche LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2025.
Kalaris Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- The filing was made on August 13, 2025.
- Reports financial results for the quarter ended June 30, 2025.
- Includes Exhibit 99.1 containing the full press release of financial results.
Kalaris Therapeutics, Inc. has announced the date for its 2025 annual meeting of stockholders as August 12, 2025. Due to the scheduling shift, the company has established a deadline for stockholder proposals under Rule 14a-8.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is scheduled for August 12, 2025.
- The meeting date deviates by more than 30 days from the anniversary of the 2024 meeting.
- Deadline for Rule 14a-8 stockholder proposals: June 30, 2025.
- Notice for director nominations must be received by June 30, 2025, due to a delay of more than 60 days from the first anniversary of the previous meeting.
Kalaris Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results were released via press release on May 14, 2025.
- The company is an emerging growth company.
Kalaris Therapeutics entered into new employment and severance agreements for its CEO, Andrew Oxtoby, and its SVP/CAO, Brett Hagen. Both agreements include significant 'change in control' provisions that trigger substantial severance payments and equity acceleration.
🚩 Red Flags
- Significant 'change in control' (M&A) protections for top executives suggest the company may be positioning itself for an acquisition or preparing for a liquidity event.
- Increased executive compensation and severance liabilities can impact cash runway in micro-cap biotech settings.
📋 Key Facts
- Andrew Oxtoby (CEO) signed an agreement on April 10, 2025, with a base salary of $569,100 and a target bonus of up to 55%.
- Oxtoby's change in control severance includes 12-18 months of base salary and 150% of his target bonus if terminated without cause/good reason near a merger.
- Brett Hagen (SVP & CAO) signed an offer letter amendment on April 15, 2025, adding severance protections.
- Hagen's change in control severance includes 9-12 months of base salary and 100% of his target bonus if terminated without cause/good reason near a merger.
Kalaris Therapeutics, Inc. announced the election of Leone Patterson to the Board of Directors and her appointment as Chair of the Audit Committee, effective April 3, 2025.
📋 Key Facts
- Leone Patterson elected as a Class III director, term expiring at the 2026 annual meeting.
- Ms. Patterson appointed as Chair of the Audit Committee.
- The Audit Committee now consists of Leone Patterson (Chair), Anthony Adamis, M.D., and Morana Jovan-Embiricos, Ph.D.
- The company plans to adopt a new non-employee director compensation program.
- Ms. Patterson will enter into the Company's standard form of indemnification agreement.
AlloVir, Inc. has completed a reverse merger with Kalaris Therapeutics, Inc., resulting in the combined entity operating as Kalaris Therapeutics, Inc. (KLRS). The transaction effectively makes Legacy Kalaris's business the primary focus of the combined company.
🚩 Red Flags
- Reverse merger structure: Legacy Kalaris (the target) becomes the majority owner of the public entity (AlloVir).
- Significant dilution/reorganization: The transaction involved a massive issuance of shares to Legacy Kalaris shareholders, representing more than 20% of AlloVir's outstanding stock.
📋 Key Facts
- Merger closed on March 18, 2025.
- AlloVir changed its name to Kalaris Therapeutics, Inc. following the merger.
- Legacy Kalaris shareholders will own approximately 74.47% of the combined company on a fully-diluted basis.
- Pre-closing AlloVir securityholders will own approximately 25.53% of the combined company.
- The exchange ratio for Legacy Kalaris Common Stock was 0.2016 to one share of AlloVir Common Stock.
- Ticker symbol changed from ALVR to KLRS on Nasdaq Global Market, effective March 19, 2025.
AlloVir, Inc. stockholders approved the proposed merger with Kalaris Therapeutics, Inc., including the issuance of shares exceeding 20% of outstanding stock and a change of control. The company also approved amendments to its 2020 Stock Option and Grant Plan to facilitate the transaction.
🚩 Red Flags
- Significant dilution: The issuance of shares represents more than 20% of the company's outstanding common stock, triggering Nasdaq change-of-control rules.
- Execution risk: Forward-looking statements highlight risks regarding the ability to manage operating expenses and potential depletion of cash resources pending closing.
📋 Key Facts
- Stockholders approved Proposal No. 1: Issuance of >20% of AlloVir common stock to Kalaris stockholders and a change of control via merger.
- Stockholders approved Proposal No. 2: Amendment to the 2020 Stock Option and Grant Plan, increasing shares reserved by 5% of post-merger outstanding stock.
- The Merger Agreement was originally entered into on November 7, 2024.
- A quorum was present at the Special Meeting with 3,912,840 shares represented out of 5,041,932 total shares outstanding.
- The merger is expected to be consummated as soon as practicable following remaining closing conditions.
AlloVir, Inc. has implemented a 1-for-23 reverse stock split effective January 15, 2025, following stockholder approval on January 9, 2025. The action is part of the company's strategic preparations regarding a proposed merger with Kalaris Therapeutics, Inc.
🚩 Red Flags
- Reverse stock split is often used to combat low share prices and potential Nasdaq delisting risks.
- The filing mentions the split is related to a proposed merger, which introduces significant execution risk.
📋 Key Facts
- Reverse stock split ratio: 1-for-23
- Effective date/time: January 15, 2025, at 4:05 p.m. ET
- Stockholders with fractional shares will receive cash payments in lieu of new shares.
- Trading on Nasdaq is expected to resume on a split-adjusted basis on January 16, 2025, under symbol 'ALVR'.
- New CUSIP number: 019818202.
AlloVir, Inc. has announced a 1-for-23 reverse stock split effective January 15, 2025. This action is being taken in connection with a proposed merger between AlloVir and Kalaris Therapeutics, Inc.
🚩 Red Flags
- Reverse stock split (typically used to boost share price for Nasdaq compliance or M&A requirements)
- High dilution/consolidation ratio (1-for-23)
📋 Key Facts
- Reverse stock split ratio: 1-for-23
- Effective date/time: January 15, 2025, at 4:05 p.m. ET
- Trading on a split-adjusted basis begins: January 16, 2025
- New CUSIP number: 019818202
- Fractional shares will be paid in cash based on the closing price on Jan 15, 2025
- The split is linked to a proposed merger with Kalaris Therapeutics, Inc.
AlloVir, Inc. stockholders approved a proposal to authorize the Board of Directors to implement a reverse stock split with a ratio between 1-for-15 and 1-for-35 at their discretion prior to January 10, 2026.
🚩 Red Flags
- Reverse stock split approved (typically used to boost share price or meet exchange listing requirements).
- High range of potential dilution/consolidation (up to 1-for-35).
📋 Key Facts
- Special Meeting held on January 9, 2025.
- Stockholders approved the Reverse Stock Split Proposal with 96,216,120 votes in favor and 12,082,172 votes against.
- The split ratio will be between 1-for-15 and 1-for-35.
- The Board of Directors has the discretion to determine the exact ratio without further stockholder approval.
- The reverse split is being conducted in connection with a proposed merger involving Kalaris Therapeutics, Inc.
AlloVir, Inc. announced the resignation of CEO and Director Diana Brainard, effective December 19, 2024. The company's current President and CFO, Vikas Sinha, has been appointed as the new CEO.
🚩 Red Flags
- Sudden departure of CEO/Principal Executive Officer during an active merger process (Kalaris Therapeutics).
- Significant cash outflow for executive separation package (3 years salary + bonus + $100k milestone payment).
📋 Key Facts
- CEO Diana Brainard resigned from her position as CEO and Director on Dec 19, 2024.
- The resignation was not due to any disagreement regarding operations, policies, or practices.
- Vikas Sinha (current President/CFO) appointed as new CEO effective Dec 19, 2024.
- Separation package for Dr. Brainard includes 36 months of base salary, 100% of current year target bonus, $100,000 completion fee for the Kalaris Therapeutics merger, and 18 months of COBRA.
- Vikas Sinha has a background at Alexion Pharmaceuticals and Bayer AG.
AlloVir, Inc. has entered into a definitive merger agreement to acquire Kalaris Therapeutics, Inc. in an all-stock transaction. The deal results in Kalaris stockholders owning approximately 74.95% of the combined company, with AlloVir stockholders retaining roughly 25.05%.
🚩 Red Flags
- Proposed reverse stock split as a condition/proposal of the merger.
- Significant dilution for existing AlloVir shareholders (retaining only ~25% ownership).
- Requirement for AlloVir to maintain Nasdaq listing and obtain specific shareholder approvals regarding equity issuance.
📋 Key Facts
- Merger Agreement signed on November 7, 2024.
- Kalaris stockholders will own ~74.95% of the combined entity; AlloVir stockholders will own ~25.05% (on a fully-diluted basis).
- Valuation for AlloVir is set at $116.0 million, subject to dollar-for-dollar adjustments based on net cash deviations from $100.0 million.
- Kalaris valuation is set at $347.0 million.
- AlloVir plans to seek stockholder approval for a reverse stock split as part of the merger proposals.
- The transaction includes a 180-day lock-up agreement for certain executive officers, directors, and stockholders.
- Kalaris is permitted to raise up to $15.0 million in bridge financing prior to closing ($7.5M from AlloVir, $7.5M from existing Kalaris stockholders).
AlloVir, Inc. has entered into a termination agreement to end its lease for office space in Waltham, MA, effective June 30, 2024. The company will pay an early termination fee of $7,000,000 to the landlord.
🚩 Red Flags
- Significant cash outflow ($7M) for lease termination suggests a restructuring or downsizing of physical footprint.
- The timing and cost of the exit fee may indicate pressure to reduce fixed operating expenses (burn rate).
📋 Key Facts
- Termination of Lease Agreement dated September 8, 2021 with BP Bay Colony LLC.
- Premises include ~78,541 square feet across three floors at 1100 Winter Street, Waltham, MA.
- Early Termination Date was June 30, 2024.
- The Company must pay an Early Termination Payment of $7,000,000 to the Landlord.
- Payment is due approximately five business days after July 1, 2024.
AlloVir, Inc. entered into a Sublease Termination Agreement with AMAG Pharmaceuticals, Inc. to terminate its sublease for premises in Waltham, MA. The termination is effective June 30, 2024, and requires the company to pay a $5.7 million lease termination fee.
🚩 Red Flags
- Significant cash outflow: The $5.7 million termination fee represents a material immediate cash expenditure for a micro-cap company.
- Exit from physical premises: Termination of office/lab space may indicate restructuring or cost-cutting measures.
📋 Key Facts
- Termination of Sublease Agreement dated September 8, 2021.
- Effective Termination Date: June 30, 2024 (subject to landlord approval).
- The Company will pay a Lease Termination Fee of $5,700,000 to AMAG Pharmaceuticals, Inc.
- The fee is due on or about the date of the agreement (June 5, 2024).
- Company will have no further rent obligations after June 30, 2024.
AlloVir, Inc. held its Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the successful election of three Class I directors and the ratification of Deloitte & Touche LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Record date for voting was April 15, 2024, with 114,912,515 shares outstanding.
- Class I Director nominees Juan Vera, M.D., Morana Jovan-Embiricos, Ph.D., and Derek Adams, Ph.D. were all elected to serve until the 2027 Annual Meeting.
- Proposal 2 was approved: Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Total votes cast for auditor ratification: 104,222,022 'For', 276,182 'Against', and 400,550 'Abstain'.
AlloVir, Inc. announced the Board's approval of $100,000 cash transaction bonuses for its CEO, President/CFO, and General Counsel. These bonuses are contingent upon the execution of a definitive change-of-control agreement during fiscal year 2024.
🚩 Red Flags
- Potential misalignment of incentives: Bonuses are tied specifically to a change-of-control event, which may incentivize management to pursue a sale even if it is not in the best interest of long-term shareholders.
- Related-party transaction involving top executives.
📋 Key Facts
- Transaction date: May 31, 2024.
- Bonus amount: $100,000 each for Diana Brainard (CEO), Vikas Sinha (President and CFO), and Edward Miller (General Counsel).
- Conditionality: Bonuses require the execution of a definitive agreement for a 'Strategic Transaction' (change of control) in fiscal year 2024.
- Employment requirement: Executives must remain employed through the consummation of the transaction to receive payment.
- Recusal: CEO and CFO abstained from voting on their respective bonuses.
AlloVir, Inc. received a notice from Nasdaq indicating it is non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has been granted a 180-day period to regain compliance by August 7, 2024.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price).
- Potential for an upcoming reverse stock split to regain compliance, which is often viewed negatively by the market.
- Prolonged period of low share price (<$1.00) indicating significant downward momentum.
📋 Key Facts
- Received Nasdaq notice on February 9, 2024, regarding non-compliance with Nasdaq Listing Rule 5450(a)(1).
- The stock closed below $1.00 per share for 30 consecutive business days.
- A 180-calendar day grace period is provided to regain compliance, expiring August 7, 2024.
- Compliance can be achieved by maintaining a closing bid price of at least $1.00 for 10 consecutive business days within the grace period.
- The company explicitly mentioned evaluating a reverse stock split as a potential remedy.
AlloVir, Inc. announced a massive workforce reduction of approximately 95% following the discontinuation of its three global Phase 3 posoleucel studies. The company expects to incur $13 million in restructuring charges during Q1 2024 as it attempts to preserve capital.
🚩 Red Flags
- 95% workforce reduction indicates a near-total cessation of primary R&D operations.
- Discontinuation of Phase 3 clinical trials (the most advanced stage) suggests failure of the core product pipeline.
- Significant restructuring charge ($13M) relative to company size in a capital preservation mode.
- Extreme liquidity risk implied by the need for massive headcount reduction to 'preserve capital'.
📋 Key Facts
- Workforce reduction of approximately 95% of current employees.
- Discontinuation of three global Phase 3 posoleucel studies announced on December 22, 2023.
- Expected personnel-related restructuring charges of approximately $13 million.
- Restructuring expected to be substantially completed by April 15, 2024.
- Primary goal is cost reduction and capital preservation.